Cystic Fibrosis – Deals Analytics Report, 2010 to 2019

Need more information?

Inquiry

We Offer You…

» Online support by email or telephone 24×7

» Assured confidentiality, safety and security as we operate through most trusted and reliable online payment systems

» Instant delivery of requested content in the desired form (PDF/PPT/Word Doc) to your provided email address after receiving the full payment.

» A Minimum Content Delivery initiation time of 9 hours

» An opportunity to be considered as an Expert Panel Member

» The provision of live, domain-specific updates

Cystic Fibrosis – Deals Analytics Report, 2010 to 2019

  • 41 Pages | Published On: 29-Mar-19 | Format:PDF | Last Updated: 29-Mar-19
  • “GervanoRA’s Cystic Fibrosis Deals Activity Report, 2010-2019 has analyzed and provided an understanding of the overall competition in partnering landscape in the disease area that has occurred from the year 2010.
    GervanoRA has analyzed more than 90 drug candidates in the current development pipeline. Hence, a number of emerging and clinical-stage companies are embarking with collaborations or partnerships with different pharma companies to aid in the development process of their respective drug candidates. In the light of rocketing competition, not only companies, but also universities, institutes and research centers are getting actively involved in the advancements of new medicines for the treatment of the disease.
    The report through its meticulous analysis on global therapeutic landscape of Cystic Fibrosis deals assists companies in taking future partnering decisions based on competitor’s R&D activities; current trends in partnering landscape in order to avoid or mitigate competitive market risks.
    For a proper understanding, GervanoRA has segmented the report into sections based on:
    • Analytics based on deal type,
    • Analytics based on deal by value,
    • Analytics based on geography
    • Analytics based on deal maker
    • Year-by-year analytics
    The report also includes case studies provided for the deals that were prominent and unique among all the deals.”

  • TABLE OF CONTENTS
    1 INTRODUCTION
    1.1. REPORT DESCRIPTION
    1.2. METHODOLOGY
    1.3. OTHER AVAILABLE DEALS ANALYSIS REPORTS
    1.4. ABOUT US: GERVANORA DATA SERVICES
    2 EXECUTIVE SUMMARY
    3 ANALYTICS BY DEAL TYPE
    3.1. CYSTIC FIBROSIS AGREEMENTS
    3.2. CYSTIC FIBROSIS COLLABORATIONS
    3.3. CYSTIC FIBROSIS MERGERS & ACQUISITIONS
    3.4. CYSTIC FIBROSIS FINANCING – GRANT AND FUNDING DEALS
    3.5. CYSTIC FIBROSIS LICENSING DEALS
    3.6. CYSTIC FIBROSIS ALLIANCE DEAL
    4 ANALYTICS BY DEAL VALUE AND GEOGRAPHY
    5 ANALYTICS BY ACTIVE PLAYERS
    6 ANALYTICS BY ANNUAL FREQUENCY
    7 CASE STUDIES- TOP FIVE PROMINENT DEALS
    DEAL 1: ROYALTY PHARMA ANNOUNCES $3.3 BN ROYALTY TRANSACTION WITH CYSTIC FIBROSIS FOUNDATION THERAPEUTICS
    DEAL 2: ASTRAZENECA TO SELL SMALL MOLECULE ANTIBIOTICS BUSINESS TO PFIZER
    DEAL 3: VERTEX AND PARION SCIENCES ESTABLISH COLLABORATION TO DEVELOP EPITHELIAL SODIUM CHANNEL (ENAC) INHIBITORS IN CYSTIC FIBROSIS AND OTHER PULMONARY DISEASES
    DEAL 4: VERTEX AND MODERNA ESTABLISH EXCLUSIVE COLLABORATION TO DISCOVER AND DEVELOP MRNA THERAPEUTICS FOR CYSTIC FIBROSIS
    DEAL 5: VERTEX AND CRISPR THERAPEUTICS ESTABLISH COLLABORATION TO USE CRISPR-CAS9 GENE EDITING TECHNOLOGY TO DISCOVER AND DEVELOP NEW TREATMENTS FOR GENETIC DISEASES
    8 ABBREVIATIONS

    LIST OF TABLES
    TABLE 01: MAJOR AGREEMENTS IN THE CYSTIC FIBROSIS AREA
    TABLE 02: MAJOR COLLABORATIONS IN THE CYSTIC FIBROSIS AREA
    TABLE 03: MAJOR COLLABORATIONS IN THE CYSTIC FIBROSIS AREA
    TABLE 04: MAJOR FINANCING DEALS- GRANTS AND FUNDING IN THE CYSTIC FIBROSIS AREA
    TABLE 05: MAJOR LICENSING DEALS IN THE CYSTIC FIBROSIS AREA
    TABLE 06: TOP 10 MAJOR DEALS IN THE CYSTIC FIBROSIS AREA RANKED BY DEAL AMOUNT

    LIST OF FIGURES
    FIGURE 01: CYSTIC FIBROSIS DEALS, BY DEAL TYPE
    FIGURE 02: CYSTIC FIBROSIS DEAL AMOUNT SHARE BY DEAL TYPE
    FIGURE 03: CYCTIC FIBROSIS DEALS SCENARIO, YEAR V/S DEAL AMOUNT
    FIGURE 04: PHARMACEUTICAL COMPANIES INVOLVED IN MORE THAN A SINGLE DEAL IN CF AREA
    FIGURE 05: NUMBER OF CYSTIC FIBROSIS DEALS, YEAR BY YEAR
    FIGURE 06: INCREASING AGREEMENT DEALS

Pricing

Individual Pricing $500

Corporate Pricing $500

Enterprise Pricing $500

(We are offering all the above license types for a single price!!)